Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Recurrent/Persistent Clear Cell Gynecologic Cancers
NCT06677190Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan in ovarian clear cell carcinoma (OCCC), endometrial clear cell carcinoma (ECC), Clear cell adenocarcinoma of the cervix, Vaginal clear cell carcinoma (VCCC), vulvar carcinoma, sponsored by Dana-Farber Cancer Institute. Started Dec 2024; status: recruiting.
02
Drugs
belzutifan
03
Conditions
ovarian clear cell carcinoma (OCCC)endometrial clear cell carcinoma (ECC)Clear cell adenocarcinoma of the cervixVaginal clear cell carcinoma (VCCC)vulvar carcinoma
Beyond the preview
Go deeper on NCT06677190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677190.